Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced that it has closed on $25 million of additional equity funding. The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap.
